Table 1.
Baseline characteristics of the included patients.
Table 2.
Serum levels of biomarkers at Day 1 and Month 4.
Table 3.
CMR parameters.
Table 4.
Occurrence of adverse ischemic injury.
Fig 1.
Logistic univariable regression analyses on dichotomized outcomes of ishemic injury and levels of biomarkers.
Day 1 (circles) and Month 4 (triangles). Odds ratio (OR) per 1 ng/ml increase in concentration. MVO, microvascular obstruction; EDV, end-diastolic volume; LVEF, left ventricular ejection fraction; MSI, myocardial salvage index; AAR, area at risk.
Table 5.
Cox proportional hazards models for the association between biomarker levels and all-cause mortality.
Fig 2.
Kaplan-Meier plots on all-cause mortality and the dichotomized biomarkers GDF-15 and syndecan-4.
Serum levels of GDF-15 at Day 1 (a), Month 4 (b), and syndecan-4 levels at Day 1 (c) and Month 4 (d) High (turquoise) and low (orange) serum levels determined with cut-off levels estimated by Liu’s method, while log-rank test was employed to compare the probability of mortality in high versus low serum levels. A p-value <0.05 was considered significant. GDF, growth differentiation factor.
Table 6.
Cut-off levels of biomarkers.
Fig 3.
ROC curves for the prediction of all-cause mortality.
Prediction based on the levels of GDF-15 at Month 4, syndecan-4 at Month 4, NT-proBNP at Month 4 and peak troponin T measured during the initial admission. ROC, receiver operating characteristics; AUC, area under the curve; GDF, growth differentiation factor; NT-proBNP, N-terminal pro-B-type natriuretic peptide.